Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review.

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Abstract Text:

H W Hirte,J E Strychowsky,T Oliver,M Fung-Kee-Fung,L Elit,A M Oza,H W Hirte,J E Strychowsky,T Oliver,M Fung-Kee-Fung,L Elit,A M Oza,H W Hirte,J E Strychowsky,T Oliver,M Fung-Kee-Fung,L Elit,A M Oza,

To determine the front-line chemotherapeutic options for women with recurrent, metastatic, or persistent cervical cancer. The Medline, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) comparing chemotherapy regimens for patients with recurrent, metastatic, or persistent cervical cancer. Studies were included if response rate, survival, toxicity, or quality of life data were reported. Fifteen RCTs were identified. The proportion of patients with prior chemoradiotherapy ranged from 0% to 57%. Four of the 15 RCTs detected significant improvements in overall response with combination cisplatin-based chemotherapy when compared with single-agent cisplatin. One of the 15 RCTs reported a significant median survival advantage with topotecan and cisplatin when compared with single-agent cisplatin (9.4 vs 6.5 months, P = 0.017); 57% of patients in this trial had previous chemoradiotherapy. Significant increases in grade 3 and 4 adverse events, especially severe hematologic toxicities, were detected among patients treated with that combination of chemotherapy. Thus, we conclude that cisplatin and topotecan should be discussed as a reasonable treatment option for appropriate patients who may wish to maximize the response and survival benefits associated with combination chemotherapy. Patients should understand that prior chemoradiotherapy with cisplatin may moderate the benefits observed, and that the relative benefits in response and survival outcomes come at the expense of increased toxicity. The improvement in median survival of 2.9 months represents a novel survival benefit in this difficult-to-treat patient population. Further randomized trials are needed to inform the role of single-agent or combination chemotherapy regimens, particularly in patients with prior chemoradiotherapy.

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Publishing Authors By Initials

HW Hirte,JE Strychowsky,T Oliver,M Fung-Kee-Fung,L Elit,AM Oza,HW Hirte,JE Strychowsky,T Oliver,M Fung-Kee-Fung,L Elit,AM Oza,HW Hirte,JE Strychowsky,T Oliver,M Fung-Kee-Fung,L Elit,AM Oza,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of gynecological cancer : of

VOLUME: 17

Page Numbers: 1194-204

Journal Abbreviation:

ISSN: 1048-891X

DAY: 1

MONTH: 06

YEAR: 2007

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9111626

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review.

AFFILIATION: Department of Medical Oncolgy, Juravinski Regional Cancer Centre, Hamilton, Ontario, Canada.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Gynecol Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review Related Publications

• A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies.
• A rare case of ectopic adrenocorticotropic hormone syndrome in small cell carcinoma of the vagina: a case report.
• Argatroban use in heparin-induced thrombocytopenia.
• Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review.
• Optimization of superior vena cava coil position and usage for transvenous defibrillation.
• Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia.
• UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.
• Urinary kallikrein and plasma renin during the reversal of renovascular hypertension in rats.